Overview
NICE is unable to make a recommendation on rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia in adults. This is because the company did not provide an evidence submission.
Last reviewed: 20 August 2026
Next review: We will review this decision if the company decides to make a submission.